Published in final edited form as:
Cancer Prev Res (Phila). 2013 January ; 6(1): 70. doi:10.1158/1940-6207.CAPR-12-0477.

Correction

Correction: A Novel Sulindac Derivative that Potently Suppresses Colon Tumor Cell Growth by Inhibiting cGMP Phosphodiesterase and Catenin Transcriptional Activity

In this article (Cancer Prev Res 2012 June;5(6):822–33), which was published in the June 2012 issue of *Cancer Prevention Research* (1), the authors neglected to include an acknowledgment of individuals who performed the synthesis of the compound used in the study. The authors apologize for the omission. The acknowledgement is as follows:

Acknowledgment

We thank Drs. Robert Reynolds, Bini Mathew, and Kocharani Jacob from Southern Research for the synthesis of sulindac benzylamine and other technical support.

References

1. Whitt JD, Li N, Tinsley HN, Chen X, Zhang W, Li Y, et al. A Novel Sulindac Derivative that Potently Suppresses Colon Tumor Cell Growth by Inhibiting cGMP Phosphodiesterase and Catenin Transcriptional Activity. Cancer Prev Res. 2012 Jun; 5(6):822–33.